EnteroMedics Inc. has retired its Senior Amortizing Convertible Notes, converted all $18.75 million in notes to shares of common stock, as part of a strategy to regain compliance with the Nasdaq requirement that it have a minimum of $2.5 million of stockholders’ equity. Read More »
Sanofi's Soliqua 100/33 product to treat adults with Type 2 diabetes is now available via prescription in U.S. pharmacies. Read More »
MiMedx Group Inc. has filed lawsuits against two former sales employees for alleged breaches of contractual and common law obligations. Read More »
Factor One Source Pharmacy, a specialty pharmacy that serves individuals with complex or hard-to-manage medications, will acquire Fast Access Specialty Therapeutics, a quickly growing pharmacy that has made a name for itself through industry-leading customer satisfaction, patient engagement and strong financial performance. Read More »
Bayer AG and Versant Ventures recently announced a partnership to launch BlueRock Therapeutics. The joint venture will utilize breakthrough treatments in stem cell technology to cure a range of diseases. Read More »
CVS Health recently launched Transform Diabetes Care, a program dedicated to helping clients improve member health outcomes. Read More »
Direct Relief recently announced that it airlifted 82 tons of medical aid to Haiti for the treatment of cholera and other diseases that have become rampant since Hurricane Matthew in October. Read More »
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, recently partnered with Lonza for the manufacture of voclosporin active pharmaceutical ingredient (API). Read More »
Genentech, a member of the Roche Group, recently announced that the primary endpoint for the Phase III HAVEN 1 study has been met. The study evaluates emicizumab prophylaxis in people 12 years of age or older with hemophilia A and inhibitors to factor VIII. Read More »
Bayer recently announced an agreement with Leica Biosystems to collaborate on developing companion diagnostic tests based on tissue samples for cancer patients. Read More »
Medical technology company Zynex updated its November orders, fourth-quarter estimate and a loan forbearance agreement. Read More »
Veloxis Pharmaceuticals will establish a warrant program for its board members and its employees with the Veloxis Board of Directors exercising, in part, an authorization pursuant to the Articles of Association. Read More »
Avella has moved its operations to a new 50,000-square-foot corporate headquarters in Phoenix. Read More »
AcelRx Pharmaceuticals presented results from its Phase 3 SAP303 study of ARX-04 at the 15th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine. Read More »
AzurRx BioPharma has partnered with Mayoly Spindler to begin a Phase II clinical trial to assess the safety and effectiveness of MS1819-SD for the treatment of patients who have exocrine pancreatic insufficiency that is the result of chronic pancreatitis. Read More »
Boehringer Ingelheim has released data from its Phase I INVICTAN-1 trial involving BI 695502, the company’s bevacizumab biosimilar candidate, which shows that the drug is a bioequivalent of Avastin, which is licensed in the U.S. and E.U. Read More »
The 2016 graduate and undergraduate student winners of the Collegiate Inventors Competition included inventions and innovations presented at the competition including the administration of therapeutic drugs at-home and engineered biological particles that destroy pesticides in residual crops. Read More »
McKesson and Health Mart support the dedication of pharmacists across all practice settings and commend the American Pharmacists Association for celebrating pharmacists’ commitment to provide customers with extraordinary service. Read More »
Array BioPharma and the U.S. Food and Drug Administration have reached an agreement regarding Special Protocol Assessment for Array’s Phase 3 trial for encorafenib and Erbitux called BEACON CRC. Read More »
Annals of Oncology published the results of a brand new post-hoc analysis from two Gilotrif Phase II trials that examined dose adjustments for patients suffering from advanced non-small cell lung cancer. Read More »
Alerts Sign-up
